HRG and cancer: One of the key findings from the Phase 2 studies of seribantumab is that HRG mRNA appears to be a clinically relevant biomarker for insensitivity to therapy identifying a significant subset of patients burdened by the presence of a substantial subset of HRG-positive cancer cells within their tumors potentially directly impacting clinical outcomes on standard therapies.